System analysis based on weighted gene co‐expression analysis identifies SOX7 as a novel regulator of hepatic stellate cell activation and liver fibrosis

Abstract

AbstractHepatic stellate cell (HSC) activation is the essential pathological process of liver fibrosis (LF). The molecular mechanisms regulating HSC activation and LF are incompletely understood. Here, we explored the effect of transcription factor SRY‐related high mobility group box 7 (SOX7) on HSC activation and LF, and the underlying molecular mechanism. We found the expression levels of SOX7 were decreased in human and mouse fibrotic livers, particularly at the fibrotic foci. SOX7 was also downregulated in primary activated HSCs and TGF‐β1 stimulated LX‐2 cells. SOX7 knockdown promoted activation and proliferation of LX‐2 cells while inhibiting their apoptosis. On the other hand, overexpression of SOX7 suppressed the activation and proliferation of HSCs. Mechanistically, SOX7 attenuates HSC activation and LF by decreasing the expression of β‐catenin and phosphorylation of Smad2 and Smad3 induced by TGF‐β1. Furthermore, overexpression of SOX7 using AAV8‐SOX7 mouse models ameliorated the extent of LF in response to CCl4 treatment in vivo. Collectively, SOX7 suppressed HSC activation and LF. Targeting SOX7, therefore, could be a potential novel strategy to protect against LF.